The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells

Program in Cell Biology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer Research (Impact Factor: 9.33). 01/2002; 61(23):8492-7.
Source: PubMed


Histone deacetylase (HDACs) regulate histone acetylation by catalyzing the removal of acetyl groups on the NH(2)-terminal lysine residues of the core nucleosomal histones. Modulation of the acetylation status of core histones is involved in the regulation of the transcriptional activity of certain genes. HDAC activity is generally associated with transcriptional repression. Aberrant recruitment of HDAC activity has been associated with the development of certain human cancers. We have developed a class of HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA), that were initially identified based on their ability to induce differentiation of cultured murine erythroleukemia cells. Additional studies have demonstrated that SAHA inhibits the growth of tumors in rodents. In this study we have examined the effects of SAHA on MCF-7 human breast cancer cells. We found that SAHA causes the inhibition of proliferation, accumulation of cells in a dose-dependent manner in G(1) then G(2)-M phase of the cell cycle, and induction of milk fat globule protein, milk fat membrane globule protein, and lipid droplets. Growth inhibition was associated with morphological changes including the flattening and enlargement of the cytoplasm, and a decrease in the nuclear:cytoplasmic ratio. Withdrawal of SAHA led to reentry of cells into the cell cycle and reversal to a less differentiated phenotype. SAHA induced differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. We propose that SAHA has profound antiproliferative activity by causing these cells to undergo cell cycle arrest and differentiation that is dependent on the presence of SAHA. SAHA and other HDAC inhibitors are currently in Phase I clinical trials. These findings may impact the clinical use of these drugs.

Download full-text


Available from: Neal Rosen, Apr 22, 2014
  • Source
    • "HDAC inhibitors, in combination with standard cytotoxic or other agents (retinoids, antiHER2 strategies, hypomethylating agents), have shown antitumor activity in vitro and in vivo [153].Vorinostat is the first available HDAC inhibitor. It has been shown to inhibit growth of both ER-positive and ER-negative breast cancer cell lines and to induce cell cycle arrest [156]. A phase II trial showed that addition of vorinostat to hormonal therapy can restore hormone responsiveness in patients with ER positive, hormone resistant metastatic breast cancer [157]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast carcinoma is currently considered as a group of diseases, differing not only in histopathologic phenotype, as indicated by histologic type and grade, but also in their protein, genetic and epigenetic molecular profile. The standard of care indicates that the core information for patient management includes data on Estrogen Receptor (ER), Progesterone Receptor (PgR) and Human Epidermal Growth Factor Receptor 2 (HER2), while there is an emerging role for the proliferation marker Ki67. These indices can be provided even in low resource settings and are indispensable for prognostication and therapeutic patient management. With the progress in molecular and translational research, there is a growing body of information on the molecular subtypes of breast carcinoma and their significance, and multigene signature assays are used to dictate prognosis and guide therapeutics in high resource settings. In addition, several cellular pathways involved in tumor growth and spread are dissected and targeted in clinical trials. Among these are the p53, RB, PI3K/Akt/mTOR and Ras/MAPK pathways, alterations associated with genetic instability and epigenetic alterations including histone methylation and acetylation, DNA methylation and microRNAs expression. The tumor immune microenvironment, including the tumor infiltrating lymphocytes (TILs) is attracting significant research interest. This review summarizes the mechanisms of function of the above factors in breast tumorigenesis with emphasis on their prognostic and predictive value and their use as therapeutic targets.
    Full-text · Article · Jan 2015 · Current molecular pharmacology
  • Source
    • "On the other hand, HDAC activity can be modified by histone deacetylase inhibitor (HDACi). In addition, it has been reported that HDACi has various functions, including the arrest of the mammalian cell cycle by blocking both the G1 and G2 phase (Yoshida and Beppu, 1988), the induction of apoptotic death in some cell lines (McBain et al., 1997; Medina et al., 1997), cell differentiation (Yoshida et al., 1987; Munster et al., 2001), anti-angiogenesis (Mie Lee et al., 2003), and anti-tumor activity (Marks, 2004; Kim et al., 2007). For many years, numerous and diverse types of HDACi have been identified, including short-chain fatty acids such as valporic acid and phenyl butyrate and hydroxamic acid derivatives such as suberoylanilide hydroxamic acid (SAHA), 6-(1,3-dioxo-1H, 3Hbenzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide (termed scriptaid), and trichostatin A (TSA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many different approaches have been developed to improve the efficiency of animal cloning by somatic cell nuclear transfer (SCNT), one of which is to modify histone acetylation levels using histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA). In the present study, we examined the effect of TSA on in vitro development of porcine embryos derived from SCNT. We found that TSA treatment (50 nM) for 24 h following oocyte activation improved blastocyst formation rates (to 22.0%) compared with 8.9% in the non-treatment group and total cell number of the blastocysts for determining embryo quality also increased significantly (). Changes in histone acetylation levels as a result of TSA treatment were examined using indirect immunofluorescence and confocal microscopy scanning. Results showed that the histone acetylation level in TSA-treated embryos was higher than that in controls at both acetylated histone H3 lysine 9 (AcH3K9) and acetylated histone H4 lysine 12 (AcH4K12). Next, we compared the expression patterns of seven genes (OCT4, ID1; the pluripotent genes, H19, NNAT, PEG1; the imprinting genes, cytokeratin 8 and 18; the trophoblast marker genes). The SCNT blastocysts both with and without TSA treatment showed lower levels of OCT4, ID1, cytokeratin 8 and 18 than those of the in vivo blastocysts. In the case of the imprinting genes H19 and NNAT, except PEG1, the SCNT blastocysts both with and without TSA treatment showed higher levels than those of the in vivo blastocysts. Although the gene expression patterns between cloned blastocysts and their in vivo counterparts were different regardless of TSA treatment, it appears that several genes in NT blastocysts after TSA treatment showed a slight tendency toward expression patterns of in vivo blastocysts. Our results suggest that TSA treatment may improve preimplantation porcine embryo development following SCNT.
    Full-text · Article · Dec 2013 · Asian Australasian Journal of Animal Sciences
  • Source
    • "We postulated that the stimulation of ROS by Tam can induce the production of 5,6- ECs. One of the major characteristics of BC cell differentiation induced by AEBS ligands is the stimulation of triacylglycerol (TAG) biosynthesis [23] [24] [40] [43]. TAG biosynthesis is known to be under control of the oxysterol receptors Liver-X-Receptors (LXR) [44], and LXR were shown to be modulated by 5,6a-EC [45], suggesting that LXR could contribute to the oxysterol-dependent activity of Tam. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tamoxifen (Tam) is a selective estrogen receptor modulator (SERM) that remains one of the major drugs used in the hormonotherapy of breast cancer (BC). In addition to its SERM activity, we recently showed that the oxidative metabolism of cholesterol plays a role in its anticancer pharmacology. We established that these effects were not regulated by the ER but by the microsomal antiestrogen binding site/cholesterol-5,6-epoxide hydrolase complex (AEBS/ChEH). The present study aimed to identify the oxysterols that are produced under Tam treatment and to define their mechanisms of action. Tam and PBPE (a selective AEBS/ChEH ligand) stimulated the production and the accumulation of 5,6α-epoxy-cholesterol (5,6α-EC), 5,6α-epoxy-cholesterol-3β-sulfate (5,6-ECS), 5,6β-epoxy-cholesterol (5,6β-EC) in MCF-7 cells through a ROS-dependent mechanism, by inhibiting ChEH and SULT2B1b, the enzyme that sulfates 5,6α-EC. We showed that only 5,6α-EC was responsible for the induction of triacylglycerol (TAG) biosynthesis by Tam and PBPE, through the modulation of the oxysterol receptor LXRβ. The cytotoxicity mediated by Tam and PBPE was triggered by 5,6β-EC through an LXRβ-independent route and by 5,6-ECS through an LXRβ-dependent mechanism. The importance of SULT2B1b was confirmed by its ectopic expression in the SULT2B1b(-) MDA-MB-231 cells, which became sensitive to 5,6α-EC, Tam or PBPE at a comparable level to MCF-7 cells. This study established that 5,6-EC metabolites contribute to the anticancer pharmacology of Tam and highlights a novel signaling pathway that points to a rationale for re-sensitizing BC cells to Tam and AEBS/ChEH ligands.
    Full-text · Article · Mar 2013 · Biochemical pharmacology
Show more